Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8N0X7

UPID:
SPART_HUMAN

ALTERNATIVE NAMES:
Spastic paraplegia 20 protein; Trans-activated by hepatitis C virus core protein 1

ALTERNATIVE UPACC:
Q8N0X7; O60349; Q86Y67; Q9H1T2; Q9H1T3

BACKGROUND:
The protein Spartin, with alternative names such as Spastic paraplegia 20 protein, is implicated in crucial cellular functions including endosomal trafficking and microtubule dynamics. Its participation in cytokinesis underscores its importance in cell division.

THERAPEUTIC SIGNIFICANCE:
Mutations in Spartin are responsible for Spastic paraplegia 20, characterized by progressive leg weakness and spasticity. Exploring Spartin's role offers a promising avenue for developing targeted therapies for this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.